DE3814521A1 - Neue anwendung von dopaminrezeptor-agonisten - Google Patents
Neue anwendung von dopaminrezeptor-agonistenInfo
- Publication number
- DE3814521A1 DE3814521A1 DE3814521A DE3814521A DE3814521A1 DE 3814521 A1 DE3814521 A1 DE 3814521A1 DE 3814521 A DE3814521 A DE 3814521A DE 3814521 A DE3814521 A DE 3814521A DE 3814521 A1 DE3814521 A1 DE 3814521A1
- Authority
- DE
- Germany
- Prior art keywords
- day
- dopamine receptor
- pharmaceutical composition
- smoking
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title claims abstract description 19
- 229960002802 bromocriptine Drugs 0.000 claims abstract description 18
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims abstract description 17
- 206010057852 Nicotine dependence Diseases 0.000 claims abstract description 8
- 208000025569 Tobacco Use disease Diseases 0.000 claims abstract description 8
- 230000000391 smoking effect Effects 0.000 claims description 24
- 241000208125 Nicotiana Species 0.000 claims description 22
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229960003587 lisuride Drugs 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 229960004851 pergolide Drugs 0.000 abstract description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 abstract description 2
- JKAHWGPTNVUTNB-IXPVHAAZSA-N lergotrile Chemical compound C1=CC([C@H]2C[C@@H](CC#N)CN([C@@H]2C2)C)=C3C2=C(Cl)NC3=C1 JKAHWGPTNVUTNB-IXPVHAAZSA-N 0.000 abstract 1
- 229950007886 lergotrile Drugs 0.000 abstract 1
- 235000019504 cigarettes Nutrition 0.000 description 16
- 239000000779 smoke Substances 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 7
- 235000019788 craving Nutrition 0.000 description 6
- 239000000556 agonist Substances 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 206010043903 Tobacco abuse Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- -1 Compound bromocriptine mesylate Chemical class 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4775387A | 1987-05-07 | 1987-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3814521A1 true DE3814521A1 (de) | 1988-11-17 |
Family
ID=21950776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3814521A Withdrawn DE3814521A1 (de) | 1987-05-07 | 1988-04-29 | Neue anwendung von dopaminrezeptor-agonisten |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS63287723A (enExample) |
| KR (1) | KR880013556A (enExample) |
| AU (1) | AU622614B2 (enExample) |
| CH (1) | CH675834A5 (enExample) |
| DE (1) | DE3814521A1 (enExample) |
| DK (1) | DK245388A (enExample) |
| FR (1) | FR2614789B1 (enExample) |
| GB (1) | GB2204240B (enExample) |
| IT (1) | IT1219564B (enExample) |
| NL (1) | NL8801171A (enExample) |
| PH (1) | PH25495A (enExample) |
| SE (1) | SE8801708L (enExample) |
| ZA (1) | ZA883237B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797405A (en) * | 1987-10-26 | 1989-01-10 | Eli Lilly And Company | Stabilized pergolide compositions |
| DE19626621A1 (de) * | 1996-07-02 | 1998-01-08 | Hexal Ag | Pflaster zur transdermalen Anwendung von Pergolid |
| US6623752B1 (en) | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR861128B (en) * | 1985-05-06 | 1986-08-26 | Sandoz Ag | New use of dopamine agonists |
| DE3722383A1 (de) * | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
-
1988
- 1988-04-29 DE DE3814521A patent/DE3814521A1/de not_active Withdrawn
- 1988-05-02 FR FR888805957A patent/FR2614789B1/fr not_active Expired - Lifetime
- 1988-05-03 IT IT47906/88A patent/IT1219564B/it active
- 1988-05-04 CH CH1664/88A patent/CH675834A5/de not_active IP Right Cessation
- 1988-05-04 NL NL8801171A patent/NL8801171A/nl not_active Application Discontinuation
- 1988-05-04 GB GB8810509A patent/GB2204240B/en not_active Expired - Lifetime
- 1988-05-05 DK DK245388A patent/DK245388A/da not_active Application Discontinuation
- 1988-05-05 AU AU15605/88A patent/AU622614B2/en not_active Expired - Fee Related
- 1988-05-05 ZA ZA883237A patent/ZA883237B/xx unknown
- 1988-05-05 SE SE8801708A patent/SE8801708L/ not_active Application Discontinuation
- 1988-05-06 JP JP63109280A patent/JPS63287723A/ja active Pending
- 1988-05-06 PH PH36895A patent/PH25495A/en unknown
- 1988-05-06 KR KR1019880005250A patent/KR880013556A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SE8801708L (sv) | 1988-11-08 |
| FR2614789B1 (fr) | 1991-10-18 |
| SE8801708D0 (sv) | 1988-05-05 |
| ZA883237B (en) | 1990-01-31 |
| NL8801171A (nl) | 1988-12-01 |
| KR880013556A (ko) | 1988-12-21 |
| DK245388D0 (da) | 1988-05-05 |
| DK245388A (da) | 1988-11-08 |
| GB8810509D0 (en) | 1988-06-08 |
| IT1219564B (it) | 1990-05-18 |
| AU1560588A (en) | 1988-11-10 |
| GB2204240A (en) | 1988-11-09 |
| CH675834A5 (enExample) | 1990-11-15 |
| GB2204240B (en) | 1991-04-24 |
| FR2614789A1 (fr) | 1988-11-10 |
| IT8847906A0 (it) | 1988-05-03 |
| PH25495A (en) | 1991-07-24 |
| AU622614B2 (en) | 1992-04-16 |
| JPS63287723A (ja) | 1988-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69811378T2 (de) | Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion | |
| AT401615B (de) | Verwendung von speziellen 5ht3-antagonisten zur herstellung von arzneimitteln | |
| DE69823520T2 (de) | Noribogain zur behandlung von schmerzen und drogenabhängigkeit | |
| DE69012591T2 (de) | Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen. | |
| DE69929041T2 (de) | Verwendung von cabergolin zur behandlung von "restless legs syndrom" | |
| DE3856096T2 (de) | Verfahren zur Behandlung der mit dem Rauchstop verbundenen Entwöhnungssymptome sowie Mittel zur Verwendung in diesem Verfahren | |
| DE69017596T2 (de) | Verwendung eines Opiatantagonisten zur Herstellung eines transdermal zu verabreichenden Arzneimittels sowie eine Vorrichtung zur transdermalen Verabreichung. | |
| DE69732189T3 (de) | Formulation von 5-ht agonisten | |
| EP1210076A2 (de) | Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid | |
| DE2856393A1 (de) | Mittel zur behandlung des zentralnervensystems | |
| DE3023588C2 (de) | Verwendung von Clonidin oder dessen Hydrochlorid zusammen mit Phentermin zum Abgewöhnen des Rauchens | |
| HUT74920A (en) | Improved nicotine lozenge and therapeutic method for smoking cessation | |
| US5480651A (en) | Composition and method for treating nicotine craving in smoking cessation | |
| US4800204A (en) | Method of controlling tobacco use | |
| DE69300608T2 (de) | Verwendung von L-Deprenyl zur Herstellung eines Arzneimittels zur Behandlung der Cushing's-Krankheit. | |
| EP1210081A2 (de) | Wirkstoffkombination enthaltend clonidin und pramipexol | |
| DE60017147T2 (de) | Verwendung von gabab-rezeptor agonisten und deren pharmazeutisch akzeptierbaren derivate bei der therapie zur erhaltung von nikotinabstinenz bei nikotinabhängigen patienten | |
| DE69803773T2 (de) | Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion | |
| DE69634662T2 (de) | Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester | |
| US5414005A (en) | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation | |
| EP2029098A2 (de) | Raucherentwöhnungs-kombinationswafer | |
| DE3814521A1 (de) | Neue anwendung von dopaminrezeptor-agonisten | |
| WO1990000896A1 (en) | USE OF BENZO(g)QUINOLINES IN TREATMENT OF NICOTINE ADDICTION | |
| DE3686097T2 (de) | Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht. | |
| DE69331008T2 (de) | Verwendung von cotinin zur linderung des tabakentzugssyndrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: MUELLER, PETER S., PRINCETON, N.J., US |
|
| 8128 | New person/name/address of the agent |
Representative=s name: VON BEZOLD, D., DR.RER.NAT. SCHUETZ, P., DIPL.-ING |
|
| 8139 | Disposal/non-payment of the annual fee |